Shuji Ota

534 total citations
27 papers, 407 citations indexed

About

Shuji Ota is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Shuji Ota has authored 27 papers receiving a total of 407 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 8 papers in Surgery. Recurrent topics in Shuji Ota's work include Cholangiocarcinoma and Gallbladder Cancer Studies (3 papers), Vestibular and auditory disorders (3 papers) and Tumors and Oncological Cases (2 papers). Shuji Ota is often cited by papers focused on Cholangiocarcinoma and Gallbladder Cancer Studies (3 papers), Vestibular and auditory disorders (3 papers) and Tumors and Oncological Cases (2 papers). Shuji Ota collaborates with scholars based in Japan and South Korea. Shuji Ota's co-authors include Yukinori Murata, Genichiro Ishii, Kaoru Kubota, Yutaka Nishiwaki, Kōichi Goto, Young Hak Kim, Atsushi Ochiai, Hideichi Shinkawa, Akira Sasaki and Seiji Kakehata and has published in prestigious journals such as SHILAP Revista de lepidopterología, Annals of Surgical Oncology and Peptides.

In The Last Decade

Shuji Ota

25 papers receiving 396 citations

Peers

Countries citing papers authored by Shuji Ota

Since Specialization

Citations

This map shows the geographic impact of Shuji Ota's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shuji Ota with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shuji Ota more than expected).

Fields of papers citing papers by Shuji Ota

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shuji Ota. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shuji Ota. The network helps show where Shuji Ota may publish in the future.

Co-authorship network of co-authors of Shuji Ota

This figure shows the co-authorship network connecting the top 25 collaborators of Shuji Ota. A scholar is included among the top collaborators of Shuji Ota based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shuji Ota. Shuji Ota is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pretreatment neutrophil-to-lymphocyte ratio predicts treatment efficacy and prognosis of cytotoxic anticancer drugs, molecular targeted drugs, and immune checkpoint inhibitors in patients with advanced non-small cell lung cancer 2021 ·Translational Lung Cancer Research ·Masashi Ishihara, (unknown), (unknown), Takahiko Sakamoto, (unknown), Takeshi Honda, Shuji Ota, Yasuko Ichikawa, Tsuyoshi Ishida, Kiyotaka Watanabe, Nobuhiko Seki	9
2	Carcinoma of Unknown Primary Site: A Mini-Review on Chemotherapy and the Expectation for Treatment with Nab-Paclitaxel Plus Carboplatin 2019 ·Yasuko Ichikawa, (unknown), (unknown), Masashi Ishihara, (unknown), Takahiko Sakamoto, (unknown), (unknown), Shuji Ota, Kiyotaka Watanabe, Nobuhiko Seki, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	1
3	Promising Combination Therapy with Bevacizumab and Erlotinib in an EGFR-Mutated NSCLC Patient with MET Amplification Who Showed Intrinsic Resistance to Initial EGFR-TKI Therapy 2019 ·Case Reports in Oncology ·Nobuhiko Seki, (unknown), (unknown), (unknown), Masashi Ishihara, (unknown), Takahiko Sakamoto, (unknown), (unknown), Takeshi Honda, Shuji Ota, Yasuko Ichikawa, Kiyotaka Watanabe	6
4	Need for Flexible Adjustment of the Treatment Schedule for Aprepitant Administration against Erlotinib-Induced Refractory Pruritus and Skin Rush 2019 ·Case Reports in Oncology ·Nobuhiko Seki, (unknown), (unknown), Masashi Ishihara, (unknown), (unknown), Takahiko Sakamoto, (unknown), (unknown), Takeshi Honda, Shuji Ota, Yasuko Ichikawa, Kiyotaka Watanabe	2
5	Significance of Earlier Initiation of Chemotherapy for Lung Cancer Complicated with Primary or Secondary Nephrotic Syndrome following Its Appropriate Differential Diagnosis 2019 ·Case Reports in Oncology ·Shuji Ota, Yoshihide Fujigaki, Yoshifuru Tamura, Kenichiro Kojima, (unknown), (unknown), Masashi Ishihara, (unknown), (unknown), Takahiko Sakamoto, (unknown), (unknown), Takeshi Honda, Yasuko Ichikawa, Kiyotaka Watanabe, Nobuhiko Seki	1
6	Successful Treatment with Taxane-Based Chemotherapy in Advanced Sebaceous Carcinoma: A Case Report and Literature Review 2019 ·Case Reports in Oncology ·Shuji Ota, Takahiko Sakamoto, (unknown), (unknown), Masashi Ishihara, (unknown), (unknown), (unknown), (unknown), Takeshi Honda, Yasuko Ichikawa, Kiyotaka Watanabe, Yuko Sasajima, Atsushi Mizota, Nobuhiko Seki	4
7	A Phase 2 Study of Induction Chemotherapy Using Docetaxel, Cisplatin, and S-1 for Gastric Cancer with Peritoneal Metastasis (KUGC06) 2019 ·Annals of Surgical Oncology ·Hiroshi Okabe, Hiroaki Hata, Hisahiro Hosogi, Shugo Ueda, Shuji Ota, Yousuke Kinjo, Nobuaki Hoshino, Shigeo Hisamori, Shigeru Tsunoda, Kazutaka Obama, Yoshiharu Sakai	6
8	A Patient with Advanced Gastric Cancer Who Achieved a Long-Term Prognosis by Early Diagnosis of Sister Mary Joseph’s Nodule 2018 ·Case Reports in Oncology ·Shuji Ota, (unknown), Masashi Ishihara, (unknown), (unknown), Takahiko Sakamoto, (unknown), (unknown), Takeshi Honda, Yasuko Ichikawa, Kiyotaka Watanabe, Yuko Sasajima, Nobuhiko Seki	3
9	A Case of Lung Adenocarcinoma with Marked Improvement of Pulmonary Lymphangitic Carcinomatosis by Adding Bevacizumab to Cisplatin and Pemetrexed 2017 ·Case Reports in Oncology ·(unknown), Takeshi Honda, (unknown), Masashi Ishihara, (unknown), Takahiko Sakamoto, (unknown), (unknown), Shuji Ota, Yasuko Ichikawa, Kiyotaka Watanabe, Nobuhiko Seki	4
10	Nivolumab-Induced Myocarditis Concomitant with Myasthenia Gravis 2017 ·Case Reports in Oncology ·(unknown), (unknown), (unknown), Makoto Nakashima, Shuji Ota, Kiyotaka Watanabe, Yoshihisa Takahashi, Fukuo Kondo, Ken Kozuma, Nobuhiko Seki	45
11	A Case of Posterior Reversible Encephalopathy Syndrome Induced by Cisplatin/Pemetrexed Chemotherapy for Lung Cancer 2017 ·Case Reports in Oncology ·Masashi Ishihara, Noriyuki Matsutani, Shuji Ota, Nobuhiko Seki	4
12	A Case of Paraneoplastic Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome Improved by Chemotherapy 2017 ·Case Reports in Oncology ·Takahiko Sakamoto, Shuji Ota, (unknown), Masashi Ishihara, (unknown), (unknown), (unknown), (unknown), Takeshi Honda, Yasuko Ichikawa, Kiyotaka Watanabe, Nobuhiko Seki	7
13	Ultrasound findings of diffuse metastasis of gastric signet-ring-cell carcinoma to the thyroid gland 2016 ·Journal of Medical Ultrasonics ·Koji Morita, Takahiko Sakamoto, Shuji Ota, (unknown), (unknown), (unknown), (unknown), Takuo Tokairin, Nobuhiko Seki, Toshio Ishikawa	3
14	Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy 2008 ·Lung Cancer ·Shuji Ota, Genichiro Ishii, Kōichi Goto, Kaoru Kubota, Young Hak Kim, Masakazu Kojika, Yukinori Murata, Manabu Yamazaki, Yutaka Nishiwaki, Kenji Eguchi, Atsushi Ochiai	103
15	Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer 2008 ·Lung Cancer ·Young Hak Kim, Genichiro Ishii, Kōichi Goto, Shuji Ota, Kaoru Kubota, Yukinori Murata, Michiaki Mishima, Nagahiro Saijo, Yutaka Nishiwaki, Atsushi Ochiai	70
16	Comparison of Intratympanic and Intravenous Dexamethasone Treatment on Sudden Sensorineural Hearing Loss with Diabetes 2006 ·Otology & Neurotology ·Seiji Kakehata, Akira Sasaki, (unknown), Kazunori Futai, Shuji Ota, (unknown), Hideichi Shinkawa	100
17	μ-Opioid receptor mRNA expression and immunohistochemical localization in the rat temporomandibular joint 2002 ·Peptides ·Katsuhiko Hayashi, (unknown), Shuji Ota, Haruyasu TANABE	17
18	Trapezoid Rotation Test by Computerized Rotary Chair System 1984 ·Practica Oto-Rhino-Laryngologica ·Jirö Hözawa, (unknown), Shuji Ota, (unknown)	1
19	Trapezoid Rotation Test by Computerized Rotary Chair System:Comparison with positional nystagmus test in patients with Meniere's disease 1984 ·Jirö Hözawa, (unknown), Shuji Ota, (unknown)	1
20	Study of L-Glutamic Acid Fermentation (II) : Bacteriological Study of L-Glutamic Acid Producing Baceria (I) : Taxonomic Study of Brevibacterium aminogenes nov. spec. 1959 ·Journal of Fermentation Technology ·Shuji Ota, Masatoshi Tanaka	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact